Redx Pharma Plc

Redx Pharma receives approval to re-commence clinical trial of RXC004

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), tells Proactive London's Andrew Scott they've received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.

It means the company is on track to restart the study as planned in the first-half.

RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.

Quick facts: Redx Pharma Plc

Price: £0.10

Market: AIM
Market Cap: £12.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...



'It's a particularly exciting time for Redx Pharma' - Capital Network's...

Capital Network's Healthcare Analyst Riccardo Lowi gives his view on Redx Pharma Plc (LON:REDX). ''The reason it's a particularly exciting time for the company is because they're moving  their two lead candidates into the clinical stage, it's the first time they're moving a drug...

on 04/03/2017

2 min read